David S. Alberts, MD | Authors




The Role of Intraperitoneal Therapy in Advanced Ovarian Cancer

February 01, 2007

Intraperitoneal (IP) chemotherapy is a preferred treatment option that should be offered to all women for front-line treatment of stage III optimally debulked ovarian cancer. Patients should be provided with information on the survival and toxicity for both IP and intravenous (IV) therapies, as well as practical information about the administration of each regimen, so that they may play an active role in the decision-making process. When making a decision between IP and IV therapeutic options, the experience and preference of the oncologist are critical factors in determining appropriate therapy for each woman.

Current Application of Selective COX-2 Inhibitors in Cancer Prevention and Treatment

May 01, 2002

The multistep process of carcinogenesis, which can take many years, provides many opportunities for intervention to inhibit disease progression. Effective chemoprevention agents may reduce the risk of cancer by inhibiting the initiation stage of carcinoma through induction of apoptosis or DNA repair in cells harboring mutations, or they may act to prevent promotion of tumor growth. Similarly, chemoprevention may entail blocking cancer progression to an invasive phenotype.

Is There a Role for Intraperitoneal Chemotherapy in the Management of Ovarian

January 01, 2001

Phase I and II clinical trial data have demonstrated the safety, pharmacokinetic advantage, and potential for enhanced cytotoxicity associated with the intraperitoneal administration of antineoplastic agents in the

Single-Agent Pegylated Liposomal Doxorubicin in Cancer: Current Status and Future Applications

October 01, 1997

The usefulness of doxorubicin (Adriamycin) in the treatment of a variety of malignancies is limited by its concomitant toxicity. The encapsulation of chemotherapeutic agents, including doxorubicin, in